BPCR
GOODBioCryst to Sell European ORLADEYO® Business for up to $264 Million
The pharmaceutical company has agreed to sell its European ORLADEYO® business for up to $264 million, allowing it to retire all remaining term debt.
BioPharma Credit
0.8800USD
0.23%
Market Cap
1.00B
Volume
196.53k
26% of avg
P/E Ratio
EPS (TTM)
N/A
Beta
N/A
Day Range
0.8800p - 0.8860p
52 Week Range
0.8000p0.8800p0.9798p
0.8800p
Upcoming Events
1 October 2025
Expected closing of the sale of European ORLADEYO® business
High Impact Event
Late 2026
Evolus Additional Tranches Availability Deadline
High Impact Event
BPCR
NEUTRALBioPharma Credit PLC Announces Holding Change
The investment company has disclosed a change in a major shareholder's holding.
BPCR
NEUTRALBioPharma Credit PLC Announces Director Appointment
The prominent investment company has announced the appointment of a new Non-Executive Director to its board.
BPCR
GOODBioPharma Credit PLC Completes OptiNose Acquisition and Invests $50 Million in Paratek Pharmaceuticals
The life sciences debt investment trust has completed the acquisition of OptiNose and made a new $50 million investment in Paratek Pharmaceuticals, strengthening its financial position.
BPCR
NEUTRALBioPharma Credit PLC Announces Director/PDMR Shareholding
The company has announced a change in shareholding by a person closely associated with a director.
BPCR
NEUTRALBioPharma Credit PLC Announces Annual General Meeting
The life sciences investment company announces details of its upcoming Annual General Meeting.
BPCR
NEUTRALBioPharma Credit PLC Provides Updates on Investments
The investment trust provides updates on partial prepayment from BioCryst Pharmaceuticals and additional investment commitment to Evolus, Inc.
BPCR
NEUTRALBioPharma Credit Announces Change in Major Shareholding
The asset manager Adage Capital Management has reduced its stake in the investment trust BioPharma Credit PLC.
BPCR
NEUTRALBioPharma Credit Receives $8.25M Settlement from Biogen
The life sciences debt investor has received a settlement payment from Biogen, resolving a dispute over a loan agreement.